$2.87−0.26 (−8.31%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Wave Life Sciences (WVE) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue is 62% below its peak, net margin −478.3%. Worth your attention in FY25: Share count (+177.2%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▼60.5%
42.7
FY21→FY25CAGR +1.1%/yr
Net income ($M)▼110.7%
−204.4
FY21→FY25CAGR —
Free cash flow ($M)▼23.9%
−188.2
FY21→FY25CAGR —
Diluted EPS▼72.9%
−1.21
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+177.2%
60.8mn → 168.6mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$718.0K
−23.5% YoY in FY25 · 1.7% of revenue.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-478¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -478.3% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 70,921.0 | 42,727.0 | 108,302.0 | 113,305.0 | 3,649.0 | 40,964.0 | ▼60.5% | +1.1% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 70,921.0 | 42,727.0 | 108,302.0 | 113,305.0 | 3,649.0 | 40,964.0 | ▼60.5% | +1.1% |
Research & development | 205,390.0 | 182,779.0 | 159,682.0 | 130,009.0 | 115,856.0 | 121,875.0 | ▲14.5% | +10.7% |
Selling, general & admin | 93,145.0 | 75,331.0 | 59,023.0 | 51,292.0 | 50,513.0 | 46,105.0 | ▲27.6% | +13.1% |
Total operating expenses | 298,535.0 | 258,110.0 | 218,705.0 | 181,301.0 | 166,369.0 | 167,980.0 | ▲18.0% | +11.3% |
Operating incomefeeds ROC rank | −227,614.0 | −215,383.0 | −110,403.0 | −67,996.0 | −162,720.0 | −127,016.0 | ▼95.1% | — |
Other income, net | 17,081.0 | 11,005.0 | 13,395.0 | 9,806.0 | 1,578.0 | 4,567.0 | — | — |
Pretax income | −210,533.0 | −204,378.0 | −97,008.0 | −58,190.0 | −161,142.0 | −122,449.0 | ▼110.7% | — |
Income tax | — | 0.0 | 0.0 | −677.0 | 681.0 | −204.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −210,533.0 | −204,378.0 | −97,008.0 | −57,513.0 | −161,823.0 | −122,245.0 | ▼110.7% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −1.06 | −1.21 | −0.70 | −0.54 | −2.05 | −2.36 | ▼72.9% | — |
Diluted shares (mn) | 204.22 | 168.65 | 138.28 | 106.10 | 78.86 | 60.84 | ▲22.0% | +29.0% |
| Margins | ||||||||
Gross margin82nd pct in Healthcare | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | ▲0.0pp | +0.0pp |
Operating margin | −320.9% | −504.1% | −101.9% | −60.0% | −4459.3% | −310.1% | ▼402.2pp | −194.0pp |
Net margin13th pct in Healthcare | −296.9% | −478.3% | −89.6% | −50.8% | −4434.7% | −298.4% | ▼388.8pp | −179.9pp |
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-26 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Wave Life Sciences' revenue last fiscal year?
Wave Life Sciences reported revenue of $42.7M in fiscal 2025, down 60.5% from fiscal 2024.
What was Wave Life Sciences' net income?
Wave Life Sciences reported net income of −$204.4M in fiscal 2025, a net margin of −478.3%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

